Brokerages forecast that Omeros Co. (NASDAQ:OMER) will announce ($0.62) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Omeros’ earnings, with estimates ranging from ($0.64) to ($0.59). Omeros posted earnings per share of ($0.23) in the same quarter last year, which would suggest a negative year over year growth rate of 169.6%. The company is scheduled to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Omeros will report full year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.55) to ($2.22). For the next fiscal year, analysts forecast that the business will post earnings of ($0.85) per share, with EPS estimates ranging from ($1.91) to $0.21. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Omeros.
Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $2.08 million. During the same period in the prior year, the business posted ($0.34) earnings per share. Omeros’s revenue for the quarter was down 87.0% compared to the same quarter last year.
NASDAQ OMER traded up $0.29 during trading hours on Friday, reaching $19.69. 476,466 shares of the company’s stock traded hands, compared to its average volume of 1,247,520. Omeros has a 52-week low of $8.36 and a 52-week high of $27.09. The stock has a market cap of $893.90 million, a P/E ratio of -24.92 and a beta of 3.63. The company has a debt-to-equity ratio of -2.91, a current ratio of 3.19 and a quick ratio of 3.18.
In other Omeros news, VP Michael A. Jacobsen sold 23,792 shares of Omeros stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $23.80, for a total value of $566,249.60. Following the completion of the transaction, the vice president now directly owns 19,480 shares of the company’s stock, valued at $463,624. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.10% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of OMER. Teacher Retirement System of Texas purchased a new position in Omeros in the fourth quarter worth about $297,000. First Trust Advisors LP purchased a new position in Omeros in the fourth quarter worth about $2,057,000. Wells Fargo & Company MN raised its holdings in Omeros by 73.4% in the fourth quarter. Wells Fargo & Company MN now owns 73,059 shares of the biopharmaceutical company’s stock worth $1,419,000 after buying an additional 30,915 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in Omeros by 93.9% in the fourth quarter. State of Wisconsin Investment Board now owns 44,600 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 21,600 shares during the last quarter. Finally, Virtus Fund Advisers LLC purchased a new position in Omeros in the fourth quarter worth about $973,000. 46.09% of the stock is owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.